Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies

Supportive Care in Cancer

Volumn 22, Issue 1, 2014, Pages 121-128

  Patel, G S ^a   Jain, K ^a   Kumar, R ^a   Strickland, A H ^b   Pellegrini, L ^b   Slavotinek, J ^c,d   Eaton, M ^a   McLeay, W ^a   Price, T ^e,f   Ly, M ^a   Ullah, S ^c   Koczwara, B ^a   Kichenadasse, G ^a   Karapetis, C S ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b Melbourne Children's Sleep Centre   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d Medical Imaging   (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Central venous catheter; Complication; Cost; Non haematological malignancy cancer; Peripherally inserted central venous catheter (PICC); Port

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CATHETER; CATHETER COMPLICATION; COST; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MALIGNANT NEOPLASTIC DISEASE; NON HAEMATOLOGICAL MALIGNANCY; NON HEMATOLOGICAL MALIGNANCY; PATIENT COMPLIANCE; PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUSLY IMPLANTED PORT CHAMBER CATHETER;

EID: 84890457002     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1941-1     Document Type: Article

References (24)

1. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
2. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047
3. Findlay M, Cunningham D (1993) Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 19:29-44
4. Kappers-Klunne MC, Degener JE, Stijnen T, Abels J (1989) Complications from long-term indwelling central venous catheters in hematologic patients with special reference to infection. Cancer 64:1747-1752
5. Worth LJ, Seymour JF, Slavin MA (2009) Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices. Support Care Cancer 17:811-818
6. Groeger JS, Lucas AB, Thaler HT et al (1993) Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 119:1168-1174
7. Hsieh CC, Weng HH, Huang WS et al (2009) Analysis of risk factors for central venous port failure in cancer patients. World J Gastroenterol 15:4709-4714
8. Ignatov A, Hoffman O, Smith B et al (2009) An 11-year retrospective study of totally implanted central venous access ports: complications and patient satisfaction. Eur J Surg Oncol 35:241-246
9. Sawayama H, Hayashi N, Watanabe M et al (2012) The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients. Surg Today 42:29-34
10. Walshe LJ, Malak SF, Eagan J, Sepkowitz KA (2002) Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 20:3276-3281
11. Sideris L LY, Barette G, et al. (2001) Long term central venous access for chemotherapy. PICC line by the radiologist or broviac by the surgeon? Eur J Cancer, 37: absract 1325.
12. Last KMJ, Oakley C, Lofts F (1998) Long-term intravenous access devices: superiority of peripherally inserted central cannulae (PICC) over hickman catheters (HC). Ann Oncol 9:142
13. Yap YS, Karapetis C, Lerose S et al (2006) Reducing the risk of peripherally inserted central catheter line complications in the oncology setting. Eur J Cancer Care (Engl) 15:342-347
14. Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267
15. Biffi R, Orsi F, Pozzi S et al (2009) Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 20:935-940
16. Tesselaar ME, Ouwerkerk J, Nooy MA et al (2004) Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 40:2253-2259
17. Marnejon T, Angelo D, Abu Abdou A, Gemmel D (2012) Risk factors for upper extremity venous thrombosis associated with peripherally inserted central venous catheters. J Vasc Access 13:231-238
18. Marinella MA, Kathula SK, Markert RJ (2000) Spectrum of upper-extremity deep venous thrombosis in a community teaching hospital. Heart Lung 29:113-117
19. Pucheu A, Evans J, Thomas D et al (1994) Doppler ultrasonography of normal neck veins. J Clin Ultrasound 22:367-373
20. Lee AY (2002) Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 28:137-140
21. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M (2001) Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning 23:1-8
22. Edwards RL, Klaus M, Matthews E et al (1990) Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med 89:25-28
23. Verso M, Agnelli G, Bertoglio S et al (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23:4057-4062
24. Couban S, Goodyear M, Burnell M et al (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23:4063-4069